Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Eli Lilly and Company

Overview

To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Breast Neoplasms

Interventions

LY353381DRUG

tamoxifenDRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria 1. Locally advanced or metastatic breast cancer 2. Bi-dimensionally measurable disease Exclusion Criteria 1\. Prior hormonal therapy

Locations (11)

Unnamed facility

Miami, Florida, United States

Unnamed facility

Shreveport, Louisiana, United States

Unnamed facility

Boston, Massachusetts, United States

Unnamed facility

Nashville, Tennessee, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.